3.0724  -0.238 (-7.18%)		05-22 14:56
Open: 3.3 High: 3.4 Volume: 111,447		Pre. Close: 3.31 Low: 3.045 Market Cap: 134(M)

Short term
Mid term
Targets	6-month :	4.56	1-year :	5.18
Resists	First :	3.9	Second :	4.44
Pivot price	3.78
Supports	First :	3.04	Second :	2.53
MAs	MA(5) :	3.55	MA(20) :	3.81
	MA(100) :	3.76	MA(250) :	5.55
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	9.1	D(3) :	22.1
RSI	RSI(14): 32.7
52-week	High :	14.59	Low :	1.79

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HURA ] has closed below the lower bollinger band by 19.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ HURA ] is to continue within current trading range. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.74 - 3.77	3.77 - 3.79
Low:	3.25 - 3.28	3.28 - 3.3
Close:	3.27 - 3.32	3.32 - 3.35

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Mon, 19 May 2025
HURA: First Quarter 2025 Results - MSN

Thu, 15 May 2025
TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update - marketscreener.com

Thu, 15 May 2025
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - PR Newswire

Mon, 05 May 2025
TuHURA Biosciences begins trial for metastatic cancer therapy - Investing.com

Wed, 02 Apr 2025
Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Tue, 01 Apr 2025
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	44 (M)
Shares Float	21 (M)
Held by Insiders	41.9 (%)
Held by Institutions	8.5 (%)
Shares Short	1,890 (K)
Shares Short P.Month	1,790 (K)

EPS	-1.22
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-90.7 %
Return on Equity (ttm)	-332.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.41
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	-2.55
PEG Ratio	0
Price to Book value	9.04
Price to Sales	0
Price to Cash Flow	-9.12

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.